Scarica l'app Stockscreener
25.03
0.89%
0.22
Precedente Chiudi:
$24.81
Aprire:
$24.87
Volume 24 ore:
170.64K
Relative Volume:
0.24
Capitalizzazione di mercato:
$1.12B
Reddito:
$681.75M
Utile/perdita netta:
$70.47M
Rapporto P/E:
17.26
EPS:
1.45
Flusso di cassa netto:
$173.19M
1 W Prestazione:
+11.74%
1M Prestazione:
+9.30%
6M Prestazione:
-5.65%
1 anno Prestazione:
+101.85%
Intervallo 1D:
$24.82
$25.26
Intervallo di 1 settimana:
$22.38
$25.50
Portata 52W:
$12.14
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Nome
Pacira Biosciences Inc
Settore
Telefono
650-242-8052
Indirizzo
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Confronta PCRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
25.03 | 1.13B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
151.93 | 66.04B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.76 | 45.57B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.6941 | 42.50B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.02 | 18.84B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
308.61 | 13.59B | 2.99B | 1.21B | 1.13B | 25.06 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-25 | Aggiornamento | Truist | Hold → Buy |
| 2025-01-30 | Aggiornamento | Truist | Sell → Hold |
| 2024-08-13 | Downgrade | Truist | Buy → Sell |
| 2024-08-12 | Downgrade | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Ripresa | JP Morgan | Overweight |
| 2023-12-20 | Iniziato | Raymond James | Outperform |
| 2023-08-03 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Ripresa | Wedbush | Outperform |
| 2022-10-21 | Ripresa | Jefferies | Buy |
| 2022-01-03 | Ripresa | JP Morgan | Overweight |
| 2021-07-26 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Ripresa | JP Morgan | Neutral |
| 2021-04-09 | Iniziato | Berenberg | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Reiterato | Needham | Buy |
| 2020-05-27 | Iniziato | Guggenheim | Neutral |
| 2020-04-07 | Iniziato | Northland Capital | Outperform |
| 2020-03-20 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-24 | Iniziato | SunTrust | Buy |
| 2020-01-23 | Iniziato | SunTrust | Buy |
| 2019-11-06 | Iniziato | BTIG Research | Buy |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-05-06 | Aggiornamento | Mizuho | Underperform → Neutral |
| 2019-05-02 | Aggiornamento | Stifel | Sell → Hold |
| 2019-02-01 | Downgrade | Mizuho | Neutral → Underperform |
| 2018-08-06 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-21 | Reiterato | Mizuho | Neutral |
| 2018-02-16 | Downgrade | Needham | Buy → Hold |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2018-01-04 | Reiterato | Canaccord Genuity | Buy |
| 2018-01-03 | Iniziato | Leerink Partners | Mkt Perform |
Mostra tutto
Pacira Biosciences Inc Borsa (PCRX) Ultime notizie
Investors Who Lost Money with Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Should Contact the Shareholders Foundation in Connection with Lawsuit - Newswire.com
Volatility clustering patterns for Pacira BioSciences Inc.July 2025 Rallies & AI Powered Market Entry Strategies - Newser
Will Pacira BioSciences Inc. stock recover after recent dropWeekly Trade Analysis & Growth Oriented Trading Recommendations - Newser
Pacira BioSciences Inc. stock trendline breakdownJuly 2025 Catalysts & Safe Investment Capital Preservation Plans - Newser
Is Pacira BioSciences Inc. building a consolidation baseFree Day Trading Signals With High Precision - Newser
Trend analysis for Pacira BioSciences Inc. this weekLong Term Stock Growth Plan Suggestions - Newser
Real time alert setup for Pacira BioSciences Inc. performanceWeekly Setup Summary for Risk Controlled Trades - Newser
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Connect - ACCESS Newswire
Exit strategy if you’re trapped in Pacira BioSciences Inc.Safe Investment Ideas with Growth Upside - Newser
Signal strength of Pacira BioSciences Inc. stock in tech scannersSupport and Resistance Zone Summary Chart - Newser
How Pacira BioSciences Inc. stock performs during market volatilityAI Enhanced Strategy for Portfolio Growth - Newser
Pacira BioSciences Inc (NASDAQ: PCRX) Yet To Convince Analysts? - stocksregister.com
Will a bounce in Pacira BioSciences Inc. offer an exitEntry and Exit Strategy for Swing Traders - Newser
Detecting price anomalies in Pacira BioSciences Inc. with AIFundamental Analysis for Value Stock Selection - Newser
Earnings visualization tools for Pacira BioSciences Inc.Free Short Term Buy Zone Stock Alerts - Newser
Order flow analysis tools used on Pacira BioSciences Inc.Free Real Profit Trade Plan Suggestions - Newser
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Pacira announces layoffs due to efficiencies in Exparel production - MSN
Doma Perpetual's 5.7% Stake in Pacira Biosciences: A Catalyst for Governance Change or Strategic Alignment? - AInvest
Analysts Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $25.75 - Defense World
Doma Perpetual Discloses 5.7% Stake in Pacira Biosciences - MarketScreener
Can machine learning forecast Pacira BioSciences Inc. recoveryRisk Balanced Picks for Safer Trading - Newser
Pacira BioSciences, Inc. (NASDAQ:PCRX) Position Lifted by Zurcher Kantonalbank Zurich Cantonalbank - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q2 2025 Earnings Call Transcript - Insider Monkey
Can Pacira BioSciences Inc. rally from current levelsStrong Buy Opportunity with Volume Support - Newser
Pacira Biosciences Q2 Earnings Call Highlights Growth and Strategy Amid Challenges - AInvest
Pacira BioSciences Reports Q2 2025 Results: EPS of -$0.11 Misses Estimates, Revenue at $181.1 Million Below Expectations - AInvest
Pacira BioSciences Reports Q2 2025 Financial Results: $181.1M Revenue, Net Loss of $4.8M - AInvest
New Product Launches: Will They Boost Pacira BioSciences Inc. Stock in 2025Momentum Entry Alerts with Risk Control - Newser
Pacira Biosciences shares rise 2.09% intraday after Q2 revenue beat expectations. - AInvest
Pacira Biosciences Q2 Non-GAAP Earnings Fall, Revenue Rises; Updates 2025 Sales Forecast - MarketScreener
Pacira BioSciences Posts Strong Q2 Growth, Boosts 2025 Revenue Guidance - AInvest
Pacira BioSciences (PCRX) Bolsters Growth with Strategic Moves - GuruFocus
Pacira BioSciences Inc (PCRX) Q2 2025 Earnings Call Highlights: Strong Growth in EXPAREL Sales ... - Yahoo Finance
Pacira BioSciences Inc (PCRX) Q2 2025 Earnings Call Highlights: Strong Growth in EXPAREL Sales ... By GuruFocus - Investing.com Canada
Pacira BioSciences' Q2 2025: Contradictions Surface on EXPAREL Market Access, Sales, and Margins - AInvest
Pacira BioSciences Q2 2025 Earnings Call Transcript: Key Takeaways - AInvest
Pacira BioSciences Inc (PCRX) Q2 2025 Earnings Call Highlights: - GuruFocus
Pacira BioSciences Q2 2025 Earnings Call Transcript - MarketBeat
Pacira BioSciences Reports Q2 2025 Financial Results - TipRanks
Decoding Pacira BioSciences Inc (PCRX): A Strategic SWOT Insight - GuruFocus
Pacira BioSciences: A Strategic Turnaround in the Opioid-Alternative Sector - AInvest
Pacira Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Pacira BioSciences' Q2 revenue misses estimates - MarketScreener
Pacira BioSciences reports Q2 2025 rev. $181.1mln, net loss $4.8mln. - AInvest
Pacira BioSciences Reports Second Quarter 2025 Financial Results - GlobeNewswire
Pacira Biosciences Inc Azioni (PCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):